Facilitated By

San Antonio Medical Foundation

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE RANGING STUDY EVALUATING THE SAFETY, PHARMACOKIETICS AND CLINICAL BENEFIT OF SLU-IGIV IN HOSPITALIZED PATIENTS WITH SERIOUS INFLUENZA A INFECTION

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Delorenzo, Robert A
Funded by
EMERGENT BIOSOLUTIONS CANADA, INC.
Research Start Date
Status
Active
Collaborative Project
Clinical Care
Drug Discovery
Infectious Disease